A biotechnology company announced Thursday that its investigational treatment for a muscle-wasting condition successfully achieved its primary endpoint in advanced clinical testing.
The company reported that the experimental therapy designed to address muscle-wasting disorders reached its main objective during the late-stage trial, representing a key milestone in the treatment’s development process.
